… potential signs of PD to, hopefully, prevent the disease from ever coming on. The next steps for  αSyn-SAA are to: … Fine tune the test so that it can distinguish PD from similar diseases, like MSA, more precisely. Early … but more work is necessary. Quantify results — move from a yes-no to a measurable result and see if and how …

… is something that is tremendously important, both from a clinical point of view for patients, but also from a regulatory point of view," he said. "If you tell … for Azilect is for use to slow clinical progression, "from our point of view, there's little to no difference …

… interesting is that some people can experience benefits from psilocybin therapy that last a lot longer than this … for regulating mood and many other brain functions. And from pre-clinical (non-human) research, we’ve also learned … plus depression and/or anxiety.   With positive results from that study, we’re now running a trial that will enroll …

… print production process, ensuring high-quality outputs from concept to final product for a range of projects across … print production process, ensuring high-quality outputs from concept to final product for a range of projects across … & Vendor Oversight Oversee end-to-end production, from scoping and vendor selection to proofing, quality …

… Services to develop the NPP and seat its advisory council. From calls, emails and in-person meetings with members of … to life in Washington, D.C., as 276 Parkinson’s advocates from 45 states (and D.C.) attended our 2025 Parkinson’s …

… Objective/Rationale:  Loss of dopamine-producing neurons in Parkinson’s disease (PD) is accompanied by inflammation in surrounding support cells, called glial cells. This inflammatory state in glial cells leads to … for oral drug delivery. Relevance to Diagnosis/Treatment of Parkinson’s Disease:   Neuroinflammation is now understood …